UPDATE -- Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe
24. Mai 2016 12:25 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 24, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based...
Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe
23. Mai 2016 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 23, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based...